PAVmed (PAVM) Stock: Buy, Sell, or Hold?
PAVM - PAVmed Inc. Common Stock
$4.18
-0.09 (-2.11%)
▼
5d:
-17.88%
30d:
-0.71%
90d:
-14.52%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When PAVM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PAVM is down 17.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PAVM is down 17.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PAVM is currently trading at $4.18, which is considered oversold relative to its 30-day fair value range of $4.62 to $5.28.
Technical Outlook: Technically, PAVM is in a strong downtrend. The price is currently testing key support at $4.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PAVM scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.50 (+773.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PAVM is in a strong downtrend. The price is currently testing key support at $4.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PAVM scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.50 (+773.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.62 -
$5.28
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 773.2% below Wall St target ($36.50)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.62 -
$5.28
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.11
Resistance Level
$5.65
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.76
Wall Street Target
$36.50
(+773.2%)
Revenue Growth (YoY)
450.0%
Share & Embed Analysis
Last updated: September 12, 2026 8:00 PM ET
Data refreshes hourly during market hours. Next update: 9:00 PM
Data refreshes hourly during market hours. Next update: 9:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PAVM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 44 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
